Roivant to present Phase 2 PHocus mosliciguat topline data in PH-ILD at ERS Congress Sept. 8, 2026
ROIV•Phase 2 PHocus topline readout scheduled for ERS Congress
Roivant flagged upcoming topline results from its Phase 2 PHocus study of mosliciguat in pulmonary hypertension tied to interstitial lung disease.
Results have not been presented yet; the readout is scheduled for the ERS Congress 2026 on Sep. 8, 2026.
The update sets a near-term catalyst for the inhaled drug candidate, a key program in Roivant’s pulmonary hypertension pipeline.
An investor call is set for 8:00 a.m. ET the same day to discuss the topline data.
